GlycoNex Inc., a clinical-stage biotechnology company based in New Taipei City, Taiwan, and Nippon Kayaku Co., Ltd., a Tokyo-based pharmaceutical and chemicals manufacturer, have entered a collaboration agreement to co-develop GNX201-ADC, a preclinical-stage antibody-drug conjugate targeting solid tumors. The glycan-directed ADC is designed to selectively activate in the tumor microenvironment using GlycoNex's proprietary "Antibody Lock" masking technology. The deal was announced on March 23, 2026. Under the agreement, both companies will jointly support preclinical development activities, including optimization of the ADC construct and generation of data to support future regulatory submissions.
Financial terms of the antibody-drug conjugate collaboration were not disclosed. The announcement contained no information regarding upfront payments, development or commercial milestones, royalty rates, profit-sharing arrangements, or equity investments. The geographic scope of the agreement was also not specified. The deal is structured as a co-development partnership rather than a unidirectional license, with each party contributing distinct capabilities. GlycoNex provides its anti-Globo H antibody and conditional activation platform, while Nippon Kayaku contributes ADC linker-payload engineering and oncology drug development experience.
Deal context
GNX201-ADC is a tumor-activated ADC that targets Globo H, a tumor-associated carbohydrate antigen expressed across multiple solid tumor types including breast, ovarian, lung, and pancreatic cancers. The molecule incorporates technology developed by PrecisemAb Biotech, which engineers a protease-cleavable masking peptide onto the antibody's hinge region. This mask blocks antigen binding during systemic circulation. At the tumor site, proteases overexpressed in the microenvironment cleave the mask, restoring binding activity and enabling the ADC to engage Globo H, internalize, and deliver its cytotoxic payload. The program is at the preclinical stage. No clinical trials are registered for GNX201-ADC, and no IND filing timeline has been disclosed.
The GlycoNex ADC partnership extends the company's pipeline beyond GNX102, its lead humanized monoclonal antibody targeting abnormal glycan structures on cancer cells. GNX102 has completed a Phase 1 trial with safety and preliminary efficacy data reported. GNX201-ADC represents GlycoNex's entry into the conditionally activated ADC space, applying the Antibody Lock platform to address on-target, off-tumor toxicity — a recognized limitation of conventional ADCs directed at glycan antigens that are expressed at low levels on normal tissues. For Nippon Kayaku, the deal adds a differentiated oncology asset to a portfolio that includes marketed and developmental oncology-related pharmaceuticals.